Viewing Study NCT06142357


Ignite Creation Date: 2025-12-24 @ 6:56 PM
Ignite Modification Date: 2026-01-07 @ 4:43 AM
Study NCT ID: NCT06142357
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-24
First Post: 2023-11-16
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Sponsor: Novartis Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module